{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:04:22Z","timestamp":1773270262110,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clgc.2019.12.021","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:41:43Z","timestamp":1578444103000},"page":"e457-e472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Aristotelis","family":"Bamias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimon","family":"Tzannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Tsironis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alkistis-Maria","family":"Papatheorodidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tsiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos","family":"Fragkoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Xirokosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despoina","family":"Barbarousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roubini","family":"Zakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Varkarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraklis","family":"Mitsogiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Adamakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Alamanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Stravodimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios G.","family":"Papatsoris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios E.","family":"Dellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Drivalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Ntoumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haris","family":"Matsouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis","family":"Halvatsiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Raptis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigorios T.","family":"Gerotziafas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.12.021_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/bjc.2015.406","article-title":"Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort","volume":"114","author":"Ahern","year":"2016","journal-title":"Br J Cancer"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2019.12.021_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.13238","article-title":"Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery; a single center experience","volume":"117","author":"Chen","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.12.021_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/bjc.2012.401","article-title":"Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival","volume":"107","author":"Gary","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib5","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e337","article-title":"Thrombosis and cancer: emerging data for the practicing oncologist","author":"Lyman","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2019.12.021_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0003319715614945","article-title":"Venous thromboembolism in patients diagnosed with lung cancer","volume":"67","author":"Salla","year":"2016","journal-title":"Angiology"},{"key":"10.1016\/j.clgc.2019.12.021_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2015-01-625582","article-title":"When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2019.12.021_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<180::AID-CNCR24>3.0.CO;2-S","article-title":"Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis","volume":"83","author":"Hettiarachchi","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib9","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2019.12.021_bib10","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update, 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib14","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2019.12.021_bib15","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2019.12.021_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2017.06.021","article-title":"Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer\u2014a retrospective cohort study","volume":"157","author":"Kruger","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.clgc.2019.12.021_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A\u00a0modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-018-1120-9","article-title":"Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients","volume":"35","author":"Rupa-Matysek","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib19","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clgc.2019.12.021_bib20","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A\u00a0predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS\u2013Cancer-Associated Thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2019.12.021_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jcp.2011.088948","article-title":"The angiome: a new concept in cancer biology","volume":"64","author":"Blann","year":"2011","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clgc.2019.12.021_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1593\/neo.05592","article-title":"Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer","volume":"8","author":"Goon","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.clgc.2019.12.021_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(01)00619-2","article-title":"Cancer and the prothrombotic state","volume":"3","author":"Lip","year":"2002","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2019.12.021_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2019.12.021_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/14740330802374262","article-title":"Gemcitabine: vascular toxicity and prothrombotic potential","volume":"7","author":"Dasanu","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clgc.2019.12.021_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-20315-3_6","article-title":"Thrombotic risk from chemotherapy and other cancer therapies","volume":"179","author":"Jiang","year":"2019","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clgc.2019.12.021_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/rej.2010.1141","article-title":"Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention","volume":"14","author":"Ferroni","year":"2011","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.clgc.2019.12.021_bib28","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clgc.2019.12.021_bib29","first-page":"E4","article-title":"Drug-related thrombosis in hematologic malignancies","volume":"8","author":"Nadir","year":"2004","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.clgc.2019.12.021_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies\u2014focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.clgc.2019.12.021_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mahe","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clgc.2019.12.021_bib33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.clgc.2019.12.021_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"van Es","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.clgc.2019.12.021_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/1076029616668405","article-title":"The Khorana score in predicting venous thromboembolism for patients with metastatic urothelial carcinoma and variant histology treated with chemotherapy","volume":"23","author":"Ramos","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clgc.2019.12.021_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2016.05.009","article-title":"High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: a systematic review and meta-analysis","volume":"34","author":"Gopalakrishna","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cam4.986","article-title":"Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival","volume":"6","author":"Ramos","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cncr.29801","article-title":"The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents","volume":"122","author":"Tully","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib39","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assn"},{"key":"10.1016\/j.clgc.2019.12.021_bib41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/1536867X1801700415","article-title":"Estimating receiver operative characteristic curves for time-dependent outcomes: the Stroccurve package","volume":"17","author":"Cattaneo","year":"2017","journal-title":"Stata J"},{"key":"10.1016\/j.clgc.2019.12.021_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.clgc.2019.12.021_bib43","first-page":"2021","article-title":"High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy","volume":"160","author":"Czaykowski","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.12.021_bib44","first-page":"259","article-title":"Non\u2013vitamin K antagonist oral anticoagulants in medical conditions at high risk of thromboembolism beyond atrial fibrillation","volume":"21","author":"Hong","year":"2019","journal-title":"J\u00a0Stroke"},{"key":"10.1016\/j.clgc.2019.12.021_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.seminoncol.2016.11.009","article-title":"The use of novel oral anticoagulants in cancer patients with venous thromboembolism","volume":"43","author":"Karakatsanis","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0037-1607436","article-title":"Use of non\u2013vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clgc.2019.12.021_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2019.12.021_bib48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib49","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.12.021_bib51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mds583","article-title":"Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine\/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16\/03)","volume":"24","author":"Bamias","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bjc.6602378","article-title":"Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study","volume":"92","author":"Ardavanis","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdj079","article-title":"Systemic chemotherapy in inoperable or metastatic bladder cancer","volume":"17","author":"Bamias","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.seminoncol.2006.12.008","article-title":"Chemotherapy for metastatic or unresectable bladder cancer","volume":"34","author":"Bellmunt","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.urolonc.2004.01.002","article-title":"A\u00a0multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer","volume":"22","author":"Kaufman","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/CAD.0b013e3280126603","article-title":"Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study","volume":"18","author":"Lin","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2019.12.021_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cncr.21604","article-title":"Combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of Hellenic Cooperative Oncology Group","volume":"106","author":"Bamias","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib58","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib59","first-page":"408","article-title":"Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer","volume":"158","author":"Kyriakakis","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.12.021_bib60","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.021_bib61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of urothelium","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.12.021_bib62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/CAD.0000000000000297","article-title":"Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by Hellenic Genitourinary Cancer Group","volume":"27","author":"Pistamaltzian","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2019.12.021_bib63","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1023\/A:1008379500436","article-title":"Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of urothelium: a multicenter phase II study of Hellenic Cooperative Oncology Group","volume":"10","author":"Dimopoulos","year":"1999","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:06Z","timestamp":1761564846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319303945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1558767319303945"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.12.021","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}